FOSCARNET SODIUM ANHYDROUS

Details

Stereochemistry	ACHIRAL
Molecular Formula	CO5P.3Na
Molecular Weight	191.9508
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O

InChI

InChIKey=DFHAXXVZCFXGOQ-UHFFFAOYSA-K

InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3

HIDE SMILES / InChI

Molecular Formula	CO5P
Molecular Weight	122.9815
Charge	-3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020068s017lbl.pdf | https://www.drugs.com/cdi/foscarnet.html

Foscarnet is an antiviral agent. Foscarnet shows activity against human herpesviruses and HIV. Foscarnet is used for treating eye problems caused by CMV in people with AIDS. It is also used to treat a type of HSV that cannot be treated by another medicine in people with a weak immune system. FOSCAVIR is the brand name for foscarnet sodium. FOSCAVIR is an organic analogue of inorganic pyrophosphate that inhibits replication of herpesviruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). FOSCAVIR exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virusspecific DNA polymerases at concentrations that do not affect cellular DNA polymerases. FOSCAVIR does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to FOSCAVIR.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Human herpesvirus 1 DNA polymerase 19 Target ID: CHEMBL1872 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020068s017lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/6298425 \| https://www.ncbi.nlm.nih.gov/pubmed/15673740	Inhibitor 8297
Human immunodeficiency virus type 1 reverse transcriptase 67 Target ID: CHEMBL247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7524439 \| https://www.ncbi.nlm.nih.gov/pubmed/9240351	Inhibitor 8297	2.03 µM [IC50]
Human herpesvirus 5 DNA polymerase 18 Target ID: CHEMBL3414 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16134946	Inhibitor 8297	2.5 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cytomegalovirus retinitis 16 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020068s017lbl.pdf	Primary		Approved 8429	FOSCAVIR Approved Use INDICATIONS CMV Retinitis FOSCAVIR is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with FOSCAVIR and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. Mucocutaneous Acyclovir Resistant HSV Infections FOSCAVIR is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS. Launch Date 1991

C_max

Value	Dose	Analyte	Population
46.4 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, oral dose: 90 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
887.3 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
64.9 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw single, oral dose: 180 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
86.2 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 1 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
78.7 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 2 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
86.4 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw 1 times / day multiple, oral dose: 180 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
589 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	60 mg/kg bw 3 times / day steady-state, intravenous dose: 60 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
623 μM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	90 mg/kg bw 2 times / day steady-state, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
300 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, oral dose: 90 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
3308 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
494 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw single, oral dose: 180 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
646 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 1 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
688 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 2 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
826 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw 1 times / day multiple, oral dose: 180 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
6.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, oral dose: 90 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw single, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw single, oral dose: 180 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 1 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	90 mg/kg bw 2 times / day multiple, oral dose: 90 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9527775/	180 mg/kg bw 1 times / day multiple, oral dose: 180 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	60 mg/kg bw 3 times / day steady-state, intravenous dose: 60 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	90 mg/kg bw 2 times / day steady-state, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
84.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	60 mg/kg bw 3 times / day steady-state, intravenous dose: 60 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:		FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
84.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf	90 mg/kg bw 2 times / day steady-state, intravenous dose: 90 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:		FOSCARNET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2400 ug 2 times / week multiple, intravitreal Highest studied dose Dose: 2400 ug, 2 times / week Route: intravitreal Route: multiple Dose: 2400 ug, 2 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/8123619/	unhealthy, 36.6 n = 11 Health Status: unhealthy Condition: AIDS Age Group: 36.6 Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/8123619/	Sources: https://pubmed.ncbi.nlm.nih.gov/8123619/
5.45 g 2 times / day multiple, intravenous Overdose Dose: 5.45 g, 2 times / day Route: intravenous Route: multiple Dose: 5.45 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	unknown, adult n = 9 Health Status: unknown Age Group: adult Sex: unknown Population Size: 9 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	Other AEs: Impaired renal function... Other AEs: Impaired renal function (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf
6.25 g 2 times / day multiple, intravenous Overdose Dose: 6.25 g, 2 times / day Route: intravenous Route: multiple Dose: 6.25 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	unknown, adult n = 1 Health Status: unknown Age Group: adult Sex: unknown Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	Other AEs: Cardio-respiratory arrest... Other AEs: Cardio-respiratory arrest (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf
60 mg/kg 2 times / day multiple, intravenous Recommended Dose: 60 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 60 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	unhealthy, adult n = 20 Health Status: unhealthy Condition: allogeneic bone marrow transplantation Age Group: adult Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	Disc. AE: Impaired renal function, Hematuria... AEs leading to discontinuation/dose reduction: Impaired renal function Hematuria Cerebral hemorrhage Physical impairment Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/

AEs

AE	Significance	Dose	Population
Impaired renal function	grade 5	5.45 g 2 times / day multiple, intravenous Overdose Dose: 5.45 g, 2 times / day Route: intravenous Route: multiple Dose: 5.45 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	unknown, adult n = 9 Health Status: unknown Age Group: adult Sex: unknown Population Size: 9 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf
Cardio-respiratory arrest	grade 5	6.25 g 2 times / day multiple, intravenous Overdose Dose: 6.25 g, 2 times / day Route: intravenous Route: multiple Dose: 6.25 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	unknown, adult n = 1 Health Status: unknown Age Group: adult Sex: unknown Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf
Cerebral hemorrhage	Disc. AE	60 mg/kg 2 times / day multiple, intravenous Recommended Dose: 60 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 60 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	unhealthy, adult n = 20 Health Status: unhealthy Condition: allogeneic bone marrow transplantation Age Group: adult Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/
Hematuria	Disc. AE	60 mg/kg 2 times / day multiple, intravenous Recommended Dose: 60 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 60 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	unhealthy, adult n = 20 Health Status: unhealthy Condition: allogeneic bone marrow transplantation Age Group: adult Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/
Impaired renal function	Disc. AE	60 mg/kg 2 times / day multiple, intravenous Recommended Dose: 60 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 60 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	unhealthy, adult n = 20 Health Status: unhealthy Condition: allogeneic bone marrow transplantation Age Group: adult Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/
Physical impairment	Disc. AE	60 mg/kg 2 times / day multiple, intravenous Recommended Dose: 60 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 60 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/	unhealthy, adult n = 20 Health Status: unhealthy Condition: allogeneic bone marrow transplantation Age Group: adult Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/10918402/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP 270 UGT 192 OAT1 326

Drug as victim

Target	Modality	Activity
CYP 270	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/7527325/	no
OAT1 326	substrate 3367 Sources: https://jpet.aspetjournals.org/content/294/3/844	no
UGT 192	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/7527325/	no

PubMed

Title	Date	PubMed
Prevention and treatment studies for CMV open.	1995 Mar-Apr	11362300
International Congress on Chemotherapy.	1995 Sep	11362904
Susceptibility of human cytomegalovirus to two-drug combinations in vitro.	1996 Dec	11324826
CMV news.	1996 Jan-Feb	11363124
Current and potential therapies for the treatment of herpesvirus infections.	2001	11548208
Treatment of gastrointestinal viruses.	2001	11444033
Current and potential therapies for the treatment of herpesvirus infections.	2001	11417115
Flow cytometric evaluation of antiviral agents against human herpesvirus 6.	2001	11345533
Prophylaxis against herpesvirus infections in transplant recipients.	2001	11270937
Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.	2001 Apr	11274081
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.	2001 Apr 1	11286223
Progressive outer retinal necrosis syndrome: successful treatment with a new combination of antiviral drugs.	2001 Apr-Jun	11456028
Cytomegalovirus treatment options in immunocompromised patients.	2001 Aug	11584992
Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.	2001 Aug	11535994
Chemoselectivity in metal cation mediated hydrolysis of a phosphonoformate diester.	2001 Aug 1	11472191
Expression dynamics of human cytomegalovirus immune evasion genes US3, US6, and US11 in the blood of lung transplant recipients.	2001 Aug 1	11443549
[Anti-hepatitis B virus effects of lamivudine and other five drugs in vitro].	2001 Aug 25	11718074
[Cytomegalovirus sensitivity to anti-retroviral agents in patients infected with the human immunodeficiency virus with chorioretinitis in Spain].	2001 Dec	11844451
Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment.	2001 Dec	11844151
Risk factors for cytomegalovirus retinitis following bone marrow transplantation from unrelated donors in patients with severe aplastic anemia or myelodysplasia.	2001 Dec	11794704
Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.	2001 Dec	11595579
Failure of cidofovir to reduce CMV-antigenemia in a child transplanted from a matched unrelated donor.	2001 Feb	11233794
Fatal primary infection due to human herpesvirus 6 variant A in a renal transplant recipient.	2001 Jan 27	11213075
Generation of hydroxyl radicals by the antiviral compound phosphonoformic acid (foscarnet).	2001 Jul	11484910
Progressive outer retinal necrosis syndrome in a lymphoma patient with good visual outcome.	2001 Jul	11438070
Differences between the quantitative antigenemia assay and the cobas amplicor monitor quantitative PCR assay for detecting CMV viraemia in bone marrow and solid organ transplant patients.	2001 Jul	11424115
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA.	2001 Jun	11551024
Progress in understanding cytomegalovirus drug resistance.	2001 Jun	11397658
Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.	2001 Jun	11353603
[Efficacy of cidofovir in an HIV infected patient with an acyclovir and foscarnet resistant herpes simplex virus infection].	2001 Jun-Jul	11460038
Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis.	2001 Mar	11280549
High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis.	2001 Mar	11239885
Frosted branch angiitis in a child with HIV infection.	2001 Mar	11239884
Persistent herpes simplex virus infection.	2001 May	11392691
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.	2001 Nov	11781649
Development of acyclovir-resistant herpes simplex virus early during the treatment of herpes neonatorum.	2001 Nov	11734722
Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child.	2001 Nov	11734717
Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo.	2001 Nov	11602788
Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.	2001 Nov 1	11577375
The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.	2001 Nov 22	11708913
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.	2001 Oct	11781635
Cytomegalovirus infection: the point in 2001.	2001 Oct	11737406
Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.	2001 Sep 1	11547769
Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.	2001 Sep 1	11547768
Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations.	2002	11785848
Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation.	2002 Feb 1	11807018
Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients.	2002 Feb 1	11774077
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.	2002 Feb 15	11830461
Drugs for non-HIV viral infections.	2002 Feb 4	11828264
[Therapeutic effect of gefin, a new antiviral drug, in experimental genital herpes ].	2002 Jan-Feb	11852781

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for CMV Retinitis Induction therapy: 90 mg/kg IV (90- to 120-minute infusion) every 12 hours or 60 mg/kg IV (minimum 1-hour infusion) every 8 hours over 2 to 3 weeks depending on clinical response Maintenance therapy: 90 to 120 mg/kg IV (2-hour infusion) once a day Usual Adult Dose for Herpes Simplex - Mucocutaneous/Immunocompromised Host Induction therapy: 40 mg/kg IV (minimum 1-hour infusion) every 8 or 12 hours Duration of therapy: 2 to 3 weeks or until healed Usual Adult Dose for CMV Gastroenteritis US CDC, NIH, and IDSA recommendations for the treatment of CMV esophagitis or colitis in HIV-infected patients: 60 mg/kg IV every 8 hours or 90 mg/kg IV every 12 hours

Route of Administration: Intravenous

In Vitro Use Guide

Foscarnet inhibits in vitro the replication of all herpes viruses, including human cytomegalovirus (HCMV) at concentrations of 100 to 300 umol/l and has a dose-related inhibitory effect on HIV-1 virus, influenza virus and hepatitis B virus.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:36:31 GMT 2023` Edited by `admin` on `Fri Dec 15 18:36:31 GMT 2023`
Record UNII	8C5OQ81LWT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FOSCARNET SODIUM ANHYDROUS

Common Name

English

foscarnet sodium [INN]

Common Name

English

Foscarnet sodium [WHO-DD]

Common Name

English

NSC-758148

Code

English

PHOSPHONOFORMIC ACID, TRISODIUM SALT

Common Name

English

FOSCARNET SODIUM [MI]

Common Name

English

PHOSPHINECARBOXYLIC ACID, 1,1-DIHYDROXY-, 1-OXIDE, SODIUM SALT (1:3)

Common Name

English

TRISODIUM PHOSPHONOFORMATE

Systematic Name

English

NSC-313410

Code

English

PHOSPHINECARBOXYLIC ACID, DIHYDROXY-, OXIDE, TRISODIUM SALT

Common Name

English

PHOSPHONOFORMIC ACID TRISODIUM SALT

Common Name

English

A-29622

Code

English

Code System Code Type Description

CAS

63585-09-1